News
2010 | 2009 | 2008 | 2007 | 2006
London, 19 November 2009
ENCOURAGING FINAL PHASE IIb RESULTS SEEN WITH LUPUZOR™ IN SYSTEMIC LUPUS ERYTHEMATOSUS
~ Greatest benefits seen in patients with moderate to severe Systemic Lupus Erythematosus ~
ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care. The study results also show that Lupuzor™ was generally well tolerated, with adverse event rates lower with Lupuzor™ when compared to placebo.
London, 19 October 2009
ImmuPharma wins 'Best Technology 2009' Award
at the AIM Awards
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company has won the Best Technology Award at the AIM Awards 2009, organized by the London Stock Exchange.
London, 9 October 2009
Appointment of Joint Broker
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce the appointment of Noble & Company Limited ("Noble") as its joint broker with immediate effect.
London, 29 September 2009
Interim Results for the six months ended 30 June 2009
ImmuPharma plc reports revenue of £21.6m
ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2009.
INTERIM HIGHLIGHTS
-
Revenue reported of £21.6m for the period following the receipt of $30m from Cephalon, Inc. as a license payment for LupuzorTM in February
-
Basic and diluted earnings per share were 15.05p and 13.69p respectively (31 December 2008: 6.23p and 5.72p respectively)
-
Strong cash position of £27m (as at 30 June 2009)
-
Interim analysis of Phase IIb data for LupuzorTM showed statistically significant superiority over placebo
-
Cephalon, Inc. exercised their right to license LupuzorTM with a $30m license payment with the potential for various future cash milestone payments totalling up to $500m as well as royalties on any future sales. Cephalon, Inc. will also assume responsibility for all future costs and activities for LupuzorTM.
-
Received 'Breakthrough of the Year 2009' European Mediscience Award
London, 21 September 2009
IMMUPHARMA TO PRESENT AT 8TH ANNUAL BIO INVESTOR FORUM
ImmuPharma PLC (LSE:IMM), the drug discovery and development group announces that Dimitri Dimitriou, Chief Executive Officer will be presenting at the 2009 BIO Investor Forum. Hosted by the Biotechnology Industry Organisation (BIO), the 8th Annual BIO Investor Forum will take place on October 28-29 at the Palace Hotel in San Francisco, California.
London, 17 September 2009
IMMUPHARMA TO PRESENT AT THE FOURTH annual jmp securities healthcare focus conference
ImmuPharma PLC (LSE:IMM) announces that Dimitri Dimitriou, Chief Executive Officer, will be presenting at the Fourth Annual JMP Securities Healthcare Focus Conference on Tuesday 6 October 2009 from 09:30am (EST) at The New York Palace Hotel, 455 Madison Avenue, NY 10022.
London, 24 July 2009
AGM Statement
ImmuPharma plc (LSE : IMM), the specialist pharmaceutical discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were passed.
London, 23 July2009
Directors' Dealings Institutions increase stake
ImmuPharma PLC ('ImmuPharma' or the 'Company') (LSE:IMM) announces that a number of existing and new blue-chip institutional investors have purchased shares from Richard Warr and the Trusts of Richard Warr and Dimitri Dimitriou, who are two of ImmuPharma's founders and Directors. A total of 12.5 million ordinary shares (16.1% of the issued share capital) of 10 pence each in the Company, were placed by Noble & Company Limited at a price of 86 pence per share to institutional investors on 23 July 2009. Panmure Gordon is the NOMAD and Corporate Broker to the Company.
London, 30 June 2009
Annual Report and Accounts
In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2008, has been posted to shareholders.
London, 24 June 2009
PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December
2008
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is pleased to announce its preliminary results for the year ended 31 December 2008.
Key Highlights:
-
Lead candidate for the treatment of Lupus, LupuzorTM, licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009
-
Interim analysis for the Phase IIb study of LupuzorTM has demonstrated statistically significant superiority of LupuzorTM over placebo
-
Data for IPP-204106 has confirmed the ability of the programme to effectively control and stop the growth of a large panel of human cancer cell lines both "in vitro" and "in vivo"
-
Awarded €1.15m in grants from prestigious French institutions for the development of the Group's promising cancer compound, IPP-204106
-
Share placings completed in July 2008 raising £2.7m before deduction of placement costs from UK and Swiss institutional investors.
-
Strong cash position due to Cephalon deal, share placings and grants awarded
London, 17 June 2009
IMMUPHARMA TO PRESENT AT THE 2009 PIPER JAFFRAY EUROPE CONFERENCE
ImmuPharma PLC ("ImmuPharma" or the "Company") (LSE:IMM) announces that Dimitri Dimitriou, Chief Executive Officer, will be presenting at the 2009 Piper Jaffray Europe Conference on Wednesday, June 24, 2009 at 12noon (BST).
London, 23 March 2009
Directors' Dealings
Institutions increase stake
ImmuPharma PLC ("ImmuPharma" or the "Company") (LSE:IMM) announces today that a number of existing and new blue-chip institutional investors have purchased shares from the Trusts of two of ImmuPharma's founders and Directors, Richard Warr and Dimitri Dimitriou.
London, 04 February 2009
Grant of Options
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, granted today share options to certain of its employees and Directors. The Company has adopted a HM Revenue & Customs approved share ownership plan (CSOP) and an unapproved share option scheme. The amount of options granted are summarised in the following table:
London, 02 February 2009
Cephalon exercises right to license Lupuzor™.
ImmuPharma to receive an additional $30m
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that Cephalon, Inc (NASDAQ: CEPH) will exercise its option to license the worldwide rights to Lupuzor™, following the recent positive interim results of ImmuPharma's Phase IIb study. Cephalon will pay ImmuPharma $30 million for licensing the worldwide rights of Lupuzor™. The various future cash milestone payments upon the achievement of certain regulatory and sales milestones (including the option and license fees) may total up to approximately $500 million. In addition to the cash milestone payments, ImmuPharma will receive royalties on commercial sales of Lupuzor™.
Cephalon will be responsible for all activities and expenses for Phase III studies, regulatory filings and subsequent commercialization of the product worldwide. It is expected that Cephalon will initiate plans to implement pivotal Phase III clinical trials this year.
London, 30 January 2009
LupuzorTM Phase
IIb study shows a positive result
and achieves statistical significance
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that a planned interim analysis of its Phase IIb clinical trial comparing Lupuzor™ to placebo in patients with systemic lupus erythematosus (also known as lupus) has demonstrated statistically significant superiority of Lupuzor™ over placebo.
During the course of its Phase IIb study an interim analysis was performed and reviewed by an independent Data Monitoring Committee according to ICH guidelines. This analysis was conducted after 125 randomized patients had completed the 12 week treatment period, half of them having also completed the additional 12 week follow-up (week 24).
The primary efficacy measure was a 'SLEDAI response' defined as a decrease of at least 4 points in the SLEDAI score, a scale generally accepted by physicians as an assessment of the clinical activity of Lupus patients, a lower score representing lower disease activity. The analysis of the data has demonstrated that the 200mcg dose of Lupuzor™ administered every four weeks was statistically significantly superior to placebo (p = 0.015). Lupuzor™ was generally well-tolerated with no significant drug related adverse events recorded. All these data follows on from the successful results which we saw with the preliminary Phase IIa trial.
